Featured Research

from universities, journals, and other organizations

New target isolated for leukemia drug development

Date:
February 11, 2014
Source:
University of Texas Health Science Center at San Antonio
Summary:
The protein WTAP and its relationship to Heat shock protein 90 are two recent discoveries that open the door to developing more effective therapies in Acute Myeloid Leukemia.

There are potentially effective treatments for acute myeloid leukemia (AML), but they only work in 20 to 40 percent of cases. In a paper published today in Leukemia, a Nature journal, a UT Health Science Center researcher has pinpointed a protein that could play a key, previously unknown role in the development of pediatric AML -- promising new information in the quest to treat and cure childhood leukemias.

AML starts at the point when cells mature into different kinds of blood cells. In AML, the cancerous cells grow and proliferate in an abnormal way, and they fail to develop, or differentiate, into normal functioning white blood cells. Also, high levels of a protein called WTAP contribute to abnormal cell behavior, observed Sanjay Bansal, Ph.D., a researcher at the Greehey Children's Cancer Research Center at The University of Texas Health Science Center at San Antonio.

Dr. Bansal and his team, working with leukemia cells, used a laboratory technique to "knock down" WTAP expression in AML cells. What resulted was, in the research world, a resounding success.

"Knocking down this protein, WTAP, greatly suppressed proliferation and induced differentiation," said Hima Bansal, Ph.D., senior research associate at the Health Science Center and lead author of the paper. "It took care of both problems."

But they needed to understand how WTAP levels get so high in AML in the first place.

The researchers turned to another protein called Hsp90, a so-called "molecular chaperone" that helps stabilize more than 200 other proteins, known as Hsp90 "clients."

"When we suppressed Hsp90, we reduced WTAP," Dr. Bansal said. "So we have discovered two things: WTAP's role in AML and the mechanism underlying its overexpression."

Many of Hsp90's other client proteins are known targets in oncology, and "WTAP joins the list," Dr. Bansal said.

This discovery could open the door to more effective therapies for children and adults with newly diagnosed AML or for patients who have failed currently available treatments.


Story Source:

The above story is based on materials provided by University of Texas Health Science Center at San Antonio. Note: Materials may be edited for content and length.


Journal Reference:

  1. H Bansal, Q Yihua, S P Iyer, S Ganapathy, D Proia, L O Penalva, P J Uren, U Suresh, J S Carew, A B Karnad, S Weitman, G E Tomlinson, M K Rao, S M Kornblau, S Bansal. WTAP is a novel oncogenic protein in acute myeloid leukemia. Leukemia, 2014; DOI: 10.1038/leu.2014.16

Cite This Page:

University of Texas Health Science Center at San Antonio. "New target isolated for leukemia drug development." ScienceDaily. ScienceDaily, 11 February 2014. <www.sciencedaily.com/releases/2014/02/140211133056.htm>.
University of Texas Health Science Center at San Antonio. (2014, February 11). New target isolated for leukemia drug development. ScienceDaily. Retrieved July 22, 2014 from www.sciencedaily.com/releases/2014/02/140211133056.htm
University of Texas Health Science Center at San Antonio. "New target isolated for leukemia drug development." ScienceDaily. www.sciencedaily.com/releases/2014/02/140211133056.htm (accessed July 22, 2014).

Share This




More Health & Medicine News

Tuesday, July 22, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com
$23.6 Billion Awarded To Widow In Smoking Lawsuit

$23.6 Billion Awarded To Widow In Smoking Lawsuit

Newsy (July 20, 2014) Cynthia Robinson claims R.J. Reynolds Tobacco Company hid the health and addiction risks of its products, leading to the death of her husband in 1996. Video provided by Newsy
Powered by NewsLook.com
Tooth Plaque Provides Insight Into Diets Of Ancient People

Tooth Plaque Provides Insight Into Diets Of Ancient People

Newsy (July 19, 2014) Research on plaque from ancient teeth shows that our prehistoric ancestor's had a detailed understanding of plants long before developing agriculture. Video provided by Newsy
Powered by NewsLook.com
Contaminated Water Kills 3 Babies in South African Town

Contaminated Water Kills 3 Babies in South African Town

AFP (July 18, 2014) Contaminated water in South Africa's northwestern town of Bloemhof kills three babies and hospitalises over 500 people. The incident highlights growing fears over water safety in South Africa. Duration: 02:22 Video provided by AFP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins